Clinical efficacy of tigecycline in the treatment of infection with carbapenem-resistant Acinetobacter baumannii
10.3969/j.issn.1671-9638.2016.06.004
- VernacularTitle:替加环素治疗耐碳青霉烯鲍曼不动杆菌感染的临床疗效
- Author:
Peng ZHANG
;
Shuyun LI
;
Chaoliang LI
;
Yantang CHEN
- Publication Type:Journal Article
- Keywords:
tigecycline;
carbapenem;
Acinetobacter baumannii;
hospital-acquired pneumonia;
bloodstream infection
- From:
Chinese Journal of Infection Control
2016;15(6):380-383
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate clinical efficacy of tigecycline alone or in combination with other antimicrobials in treating infection caused by carbapenem-resistant Acinetobacter baumannii (CRAB).Methods Patients with hos-pital-acquired pneumonia (HAP)and/or bloodstream infection in the intensive care unit of a hospital between Janu-ary 2013 and June 2014 were selected,efficacy of tigecycline treatment was analyzed.Results Of 25 patients with CRAB infection,21 were with HAP,2 with bloodstream infection,and 2 with both HAP and bloodstream infec-tion.13 cases were multidrug-resistant Acinetobacter baumannii (MDRAB), 10 cases were extensively drug-resistant Acinetobacter baumannii (XDRAB).The susceptibility rate of 25 CRAB isolates to tigecycline was 84%. After treated with tigecycline,white blood cell count(WBC),C-reactive protein (CRP),and procalcitonin (PCT) all significantly decreased (all P<0.01).The clinical effective rate,bacterial clearance rate,and 30-day mortality were 68.00% (17/25),66.67%(14/21),and 28.00% (7/25)respectively;effective rate of 21 cases of HAP was 76.19% (16/21),1 case of bloodstream infection was effective,2 cases of HAP combined bloodstream infection died.Conclusion Tigecycline is effective in the treatment of HAP caused by CRAB,but the therapeutic effect on bloodstream remains uncertain,further research is needed.
